Samarth Kulkarni, CEO, CRISPR Therapeutics

  Рет қаралды 14,497

Goldman Sachs

Goldman Sachs

Жыл бұрын

Kulkarni discusses the current state of biotechnology, the opportunities for CRISPR gene-editing therapies - and their implications for the larger pharmaceutical industry - as well as his experience leading a young company at the cutting edge of technology.
Record Date: 2/14/23

Пікірлер
СНЕЖКИ ЛЕТОМ?? #shorts
00:30
Паша Осадчий
Рет қаралды 8 МЛН
Универ. 10 лет спустя - ВСЕ СЕРИИ ПОДРЯД
9:04:59
Комедии 2023
Рет қаралды 2,6 МЛН
I wish I could change THIS fast! 🤣
00:33
America's Got Talent
Рет қаралды 63 МЛН
Jennifer Doudna: CRISPR Basics
48:26
Innovative Genomics Institute – IGI
Рет қаралды 356 М.
David Liu: A Master Class on the Future of Genome Editing
47:51
Scripps Research
Рет қаралды 3,1 М.
Geoffrey Hinton in conversation with Fei-Fei Li - Responsible AI development
1:48:12
Arts & Science - University of Toronto
Рет қаралды 117 М.
How to reboot Britain's capital markets | FT Film
20:51
Financial Times
Рет қаралды 140 М.
CRISPR Breakthroughs for Neurological Disease
58:07
Innovative Genomics Institute – IGI
Рет қаралды 6 М.
Is Gene Editing the Future?
14:45
Nanalyze
Рет қаралды 14 М.
Geoffrey Hinton | Will digital intelligence replace biological intelligence?
1:58:38
Schwartz Reisman Institute
Рет қаралды 149 М.
What Intellia investors need to pay attention to
16:33
Nanalyze
Рет қаралды 6 М.
Sustaining the Equity Rally | Bloomberg Surveillance Radio | June 24, 2024
2:56:20
CSHL Keynote, Dr. David Lebwohl, Intellia Therapeutics
1:03:51
CSHL Leading Strand
Рет қаралды 1 М.